HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years.

Abstract
Boosting adult travelers with the virosome-formulated, aluminum-free hepatitis A vaccine Epaxal up to 128 months after a single primary dose confers full protection against hepatitis A, even in travelers aged 50 years and above. Delaying the booster dose did not influence the immune memory response to Epaxal.
AuthorsChristoph Hatz, Robert van der Ploeg, Bernhard R Beck, Gert Frösner, Marjory Hunt, Christian Herzog
JournalClinical and vaccine immunology : CVI (Clin Vaccine Immunol) Vol. 18 Issue 5 Pg. 885-7 (May 2011) ISSN: 1556-679X [Electronic] United States
PMID21411599 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hepatitis A Vaccines
  • Vaccines, Virosome
  • epaxal berna
Topics
  • Adult
  • Aged
  • Female
  • Hepatitis A (immunology, prevention & control)
  • Hepatitis A Vaccines (administration & dosage, immunology)
  • Humans
  • Immunization, Secondary (methods)
  • Immunologic Memory
  • Male
  • Middle Aged
  • Time Factors
  • Vaccines, Virosome (administration & dosage, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: